197,100 Shares in ProNAi Therapeutics, Inc. (NASDAQ:SRRA) Acquired by Fmr LLC

Fmr LLC bought a new position in ProNAi Therapeutics, Inc. (NASDAQ:SRRA) during the first quarter, Holdings Channel reports. The firm bought 197,100 shares of the biotechnology company’s stock, valued at approximately $302,000.

Receive News & Ratings for ProNAi Therapeutics Inc. Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Separately, Greenleaf Trust acquired a new stake in ProNAi Therapeutics during the first quarter worth $328,000. Institutional investors own 60.30% of the company’s stock.

Shares of ProNAi Therapeutics, Inc. (NASDAQ:SRRA) opened at 1.47 on Thursday. ProNAi Therapeutics, Inc. has a 1-year low of $1.10 and a 1-year high of $2.07. The firm has a 50-day moving average of $1.31 and a 200 day moving average of $1.35. The stock’s market cap is $76.83 million.

ProNAi Therapeutics (NASDAQ:SRRA) last issued its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.07. Equities research analysts forecast that ProNAi Therapeutics, Inc. will post ($0.90) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “[[title]]” was originally posted by [[site]] and is the property of of [[site]]. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at [[permalink]].

SRRA has been the topic of a number of analyst reports. Jefferies Group LLC restated a “hold” rating on shares of ProNAi Therapeutics in a report on Thursday, July 27th. Zacks Investment Research upgraded shares of ProNAi Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th.

About ProNAi Therapeutics

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Want to see what other hedge funds are holding SRRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ProNAi Therapeutics, Inc. (NASDAQ:SRRA).